Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary EMphora™ artificial intelligence platform to identify novel precision medicine strategies designed to accelerate the development of Rakovina’s ATR inhibitor program.
asserted
Inc. → advance → program
The collaboration will initially focus on indications where EMphora™ will analyze large-scale clinical outcomes and real-world patient data to identify therapeutic targets that may enhance the activity of Rakovina’s ATR inhibitor.
uncertain
that → focus → inhibitor
In addition to evaluating potential drug combinations, the analysis will search for previously unrecognized therapeutic opportunities, predictive biomarkers, and patient subgroups most likely to benefit from ATR-targeted therapies.
asserted
analysis → evaluate → therapies
Unlike conventional preclinical discovery approaches, the collaboration will utilize artificial intelligence to interrogate real-world clinical evidence, helping identify the most promising drug combinations and patient populations before advancing into further development.
asserted
collaboration → utilize → development
By combining Rakovina’s expertise in synthetic lethality and DNA damage response therapeutics with Celvion’s AI-powered clinical discovery platform, the companies aim to improve development efficiency, reduce clinical risk, and accelerate the delivery of precision medicines to patients with difficult-to-treat cancers.
asserted
companies → combine → cancers
The companies expect the analysis to generate clinically actionable hypotheses that will help prioritize future combination studies, guide biomarker-driven patient selection strategies, and inform the design of subsequent clinical development programs.
asserted
that → expect → programs
“We have learned how to use multiple specialized AI platforms to accelerate the drug discovery and development process rather than relying on a single platform.
asserted
We → learn → platform
Our team selects the right tool for each challenge, from generative design to large-scale screening, to develop molecules that exploit vulnerabilities in how cancer cells repair DNA damage,” said Kim Oishi, Chief Executive Officer of Rakovina Therapeutics.
asserted
Oishi → select → Therapeutics
“Working with Celvion extends that approach into clinical strategy, using advanced AI to identify the patient populations and drug combinations where our ATR inhibitor program can have the greatest impact.”
asserted
program → work → impact
“EMphora was built to uncover meaningful therapeutic insights directly from clinical outcomes and existing patient data,” said Mi Yang, Chief Executive Officer of Celvion Therapeutics.
asserted
Yang → build → Therapeutics
“By collaborating with Rakovina, we have an opportunity to identify combination therapies and biomarkers that may not be apparent through conventional research methods.
uncertain
that → collaborate → methods
Our objective is to generate actionable evidence that helps guide smarter clinical development and ultimately benefits patients.”
asserted
that → generate → patients
“Synthetic lethality offers tremendous promise in oncology, but its greatest impact will come from identifying the right combinations for the right patients,” said Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina Therapeutics.
asserted
Daugaard → offer → Therapeutics
“This collaboration gives us the opportunity to rigorously evaluate ATR-based combination strategies while exploring additional biomarkers and therapeutic targets that could further enhance clinical benefit.
uncertain
that → give → benefit
These insights will help shape the next generation of our development strategy.”
asserted
insights → help → strategy
Rakovina and Celvion intend to commit appropriate scientific, technical and other resources to support the collaboration and advance the resulting opportunities.
asserted
Rakovina → intend → opportunities
As the work progresses and promising development opportunities are identified, the companies expect to explore appropriate co-development and economic arrangements to support subsequent stages of development.
asserted
companies → progress → development
The collaboration reflects Rakovina’s broader strategy of integrating cutting-edge computational biology, translational science, and precision oncology to build a smarter, faster, and more targeted approach to cancer drug development.
asserted
collaboration → reflect → development
By leveraging artificial intelligence alongside world-class science, Rakovina continues to position itself at the forefront of precision oncology innovation with the goal of delivering transformative therapies for patients facing significant unmet medical needs.
asserted
Rakovina → leverage → needs
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments.
asserted
Therapeutics → focus → treatments
Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI) using validated, proprietary platforms.
asserted
work → base → platforms
By using AI, we can review and optimize drug candidates at a much greater pace than ever before.
asserted
we → use → pace
The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.
asserted
Company → establish → partners
Further information may be found at www.rakovinatherapeutics.com.
uncertain
information → find → www.rakovinatherapeutics.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
asserted
term → define → release
Notice Regarding Rakovina Therapeutics Forward-Looking Statements:
This release includes forward-looking statements regarding the company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the company and other statements.
uncertain
which → regard → company
Often, but not always, forward-looking statements can be identified by the use of words such as “plans,” “is expected,” “expects,” “scheduled,” “intends,” “contemplates,” “anticipates,” “believes,” “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results “may,” “could,” “would,” “might,” or “will” be taken, occur, or be achieved.
uncertain
actions → look → words
Such statements are based on the current expectations of the management of the company.
asserted
statements → base → company
The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the biopharmaceutical industry, economic factors, regulatory factors, the equity markets generally, and risks associated with growth and competition.
uncertain
events → look → growth
Although the company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated, or intended.
uncertain
actions → attempt → those
No forward-looking statement can be guaranteed.
asserted
statement → look → ?
Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made, and the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
asserted
company → require → information
The reader is referred to the company’s most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the company’s profile page at www.sedar.com.
uncertain
copies → refer → www.sedar.com
The Aporia
